Study #2020-0791
An Open-label, Phase II, Pre-operative Study of Atezolizumab plus Bevacizumab for Resectable Hepatocellular Carcinoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Atezolizumab, Bevacizumab
Description
This phase II trial studies the effect of atezolizumab and bevacizumab before surgery in treating patients with liver cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving the combination of atezolizumab and bevacizumab may help to prevent liver cancer from returning after surgery.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8, Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8
Study phase:
Phase II
Physician name:
Ahmed Kaseb
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-866-254-1401
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.